Articles from Sail Biomedicines

Sail Biomedicines, a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that it will present preclinical updates from its vanguard In Vivo eRNA and targeted nanoparticle (TNP) CAR-T program and lead product candidate for autoimmune diseases at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting and TIDES USA 2026, taking place in Boston.

Sail Biomedicines, a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Martin Mackay, Ph.D., has joined its Board of Directors. Mackay is a globally recognized biopharmaceutical leader with more than three decades of executive experience driving drug discovery and development at some of the world’s leading pharmaceutical and biotechnology companies.

Sail Biomedicines, a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that it will present new preclinical data from its malaria vaccine program at the 2025 Grand Challenges Annual Meeting, taking place virtually June 1-4. The findings highlight the potential of Sail’s Endless RNA™ (eRNA) platform to enable durable antigen expression and drive potent immune responses for protection from malaria challenge.

Sail Biomedicines, a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced the presentation of preclinical data on its in vivo CAR-T product candidate, SAIL-0804, at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT 2025). The poster presentation highlights Sail’s differentiated approach to treating autoimmune diseases through transient, non-integrative T cell reprogramming using its Endless RNA™ (eRNA™) platform and targeted lipid nanoparticles (tLNPs). The data support Sail’s nomination of SAIL-0804 as its first development candidate and advancement into IND-enabling studies.

Sail Biomedicines, Inc., a Flagship Pioneering company and leader in RNA-based programmable medicines, today provided an update on its research funded by the Cystic Fibrosis Foundation (CF Foundation), with preclinical data that suggest that Sail’s Endless RNA™ (eRNA™) may offer the potential to treat the 10%-15% of people with CF for whom existing treatments are not an option.

Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Frank D’Amelio, MBA, former Chief Operating Officer (COO) of Lucent and most recently former Chief Financial Officer (CFO) and Executive Vice President, Global Supply at Pfizer, is joining Sail’s Board of Directors.